Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate.
D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001380:Azauridine / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004359:Drug Therapy, Combination; D005260:Female; D005688:Galactosamine / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012334:RNA, Neoplasm / Q000096:biosynthesis; D051381:Rats; D013268:Stimulation, Chemical; D014500:Uracil Nucleotides / Q000096:biosynthesis; D014529:Uridine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use
D004273:DNA, Neoplasm; D009943:Organophosphorus Compounds; D012334:RNA, Neoplasm; D014500:Uracil Nucleotides; D001224:Aspartic Acid; C001943:5-fluorouridine; D005688:Galactosamine; C013195:sparfosic acid; D001380:Azauridine; D010746:Phosphonoacetic Acid; D014529:Uridine